Researchers put the added odds at 37 to 68%, though absolute risk stays low
Slim-margin drugmakers warn the two-year lead time could push them out of the US market entirely
Novo Nordisk alleges their rival's advertising campaigns for its drugs are designed to mislead consumers about their superior efficacy
Three years of semaglutide cut surgeries by nearly 5% over eight years, researchers found
Reversal opens door for plan sponsors as eligible dementia population nears 1 million by 2030
Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor, and Canadian plan sponsors have reason to watch closely
